Ensiklopedia Dunia

From Wikipedia, the free encyclopedia

GamEvac-Combi
Vaccine description
Target	Ebola
Vaccine type	Heterologous
Legal status
Legal status	Registered (Russia)

GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.^[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. As of 2015^[update] the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.^[2]

Description

The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.^[3] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.^[4]

History

GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.^[2]

References

^ Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, et al. (2017). "Virus-Vectored Ebola Vaccines". Acta Naturae. 9 (3): 4–11. doi:10.32607/20758251-2017-9-3-4-11. PMC 5662269. PMID 29104771.
^ ^a ^b "Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations" (PDF). World Health Organization. Retrieved 14 August 2020.
^ Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. (March 2017). "Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia". Human Vaccines & Immunotherapeutics. 13 (3): 613–620. doi:10.1080/21645515.2016.1238535. PMC 5360131. PMID 28152326.
^ Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J (March 2019). "Ebola virus disease". Lancet. 393 (10174): 936–948. doi:10.1016/s0140-6736(18)33132-5. PMID 30777297.

v t e Gamaleya Research Institute of Epidemiology and Microbiology
Named for Nikolay Gamaleya and founded by Felix Blyumental
Directors	Alexander Gintsburg (since 1997) Sergey Prozorovsky (1982–1997)
Vaccines	Sputnik Light (COVID-19) Gam-COVID-Vac / Sputnik V (COVID-19) GamEvac-Combi (Ebola) BVRS-GamVac (MERS)
Notable employees	Garry Abelev Yuliya Ananyina [ru] Otar Andzhaparidze [ru] Oganes Baroyan [ru] Lev Gromashevsky [ru] Natalya Murashkevich Sergey Drozdov [ru] Zinaida Yermolyeva Felix Yershov [ru] Viktor Zhdanov Pavel Zdrodovsky [ru] Lev Zilber Nikolay Kaverin [ru] Eduard Korenberg [ru] Dmitry Lvov [ru] Alexey Olovnikov Yevgeny Pavlovsky Adelina-Victoria Skavronskaya [ru] Anatoly Smorodintsev [ru] Valentin Solovyov [ru] Vladimir Timakov [ru] Viktor Troitsky [ru] Alexander Fridenshteyn [ru] Mikhail Chumakov
Medical and health organizations based in Russia

Description

History

See also

References